Omeros corporation reports first quarter 2023 financial results

Seattle--(business wire)--omeros corporation (nasdaq: omer), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the first quarter ended march 31, 2023, which include.
OMER Ratings Summary
OMER Quant Ranking